DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1013856
Title:
Bacillus Collagen Like Protein of Anthracis: Immunological and Functional Analyses
Descriptive Note:
Technical Report
Corporate Author:
UNIFORMED SERVICES UNIV OF THE HEALTH SCIENCES BETHESDA MD BETHESDA United States
Report Date:
2007-09-21
Pagination or Media Count:
149.0
Abstract:
Interest in the development of an improved anthrax vaccine has increased since the 2001 bioterrorist event that involved the public dispersal of Bacillus anthracis spores through the United States postal system. The currently licensed anthrax vaccine adsorbed AVA is a crude extract in which the primary protective immunogen is the toxin binding component of the anthrax toxins, called protective antigen PA this antigen is given to elicit toxin-neutralizing antibodies in the recipient. Unfortunately, AVA has several drawbacks not the least of which are that it is administered as a six dose series over an extended period and that painful local reactions to the vaccine are commonly reported. Moreover, AVA may be less than optimally effective against the most lethal form of the disease, inhalational anthrax. Therefore, the first goal of this study was to explore the use of a B. anthracis spore surface antigen as a means of increasing protection afforded by a Protective Antigen PA - based vaccine.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
